文献速递消化系统肿瘤

卡培他滨致毒性后改用S-1辅助治疗结肠癌的安全性与可行性:荷兰人群真实世界研究

Safety and feasibility of S-1 after capecitabine-induced toxicity in the adjuvant treatment of colon cancer patients: A population-based real-world study.
PubMed 文献 · Eur J Cancer · 2026-02-17

该研究基于荷兰前瞻性结直肠癌队列(PLCRC),纳入2018年3月至2025年5月辅助治疗中因手足综合征(HFS)或心血管毒性(CVT)从卡培他滨换用S-1的55例结肠癌患者,评估辅助治疗完成率及换药后毒性。结果显示HFS组91%(21例)和CVT组97%(28例)症状减轻或完全缓解,80%(44例)完成辅助治疗,仅9%(2/23)因持续性HFS提前停药,无因CVT复发停药。S-1是辅助治疗中因卡培他滨致HFS或CVT患者的可行替代选择。

要点

  • 辅助治疗中因卡培他滨致HFS或CVT换用S-1后,91%的HFS患者和97%的CVT患者症状减轻或完全缓解。
  • 80%的患者换用S-1后能够完成辅助治疗,仅9%(2/23)因持续性HFS提前停药。
  • 无患者因CVT复发而停用S-1,提示换药后CVT控制良好。

核心结论

  • S-1是辅助治疗中因卡培他滨致HFS或CVT的结肠癌患者的可行且有用的替代选择,允许继续以氟尿嘧啶为基础的潜在治愈性治疗。

研究设计与样本

  • 基于荷兰前瞻性结直肠癌队列(PLCRC)的人群真实世界研究,纳入2018年3月至2025年5月辅助治疗中因HFS或CVT从卡培他滨换用S-1的55例结肠癌患者。

主要发现

  • 换药原因:HFS占42%(n=23),CVT占53%(n=29)。
  • HFS组91%(n=21)和CVT组97%(n=28)的患者症状减轻或完全缓解。
  • 80%(n=44)的患者换用S-1后完成辅助治疗。
  • 持续性HFS导致9%(2/23)的患者提前停药,无因CVT复发停药。

临床怎么用

  • 对于辅助治疗中因卡培他滨致HFS或CVT的结肠癌患者,可考虑换用S-1以继续氟尿嘧啶类辅助治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: S-1 has comparable efficacy to capecitabine/5-FU in metastatic colorectal cancer, but is associated with a lower incidence of hand-foot syndrome (HFS) and cardiovascular toxicity (CVT). The European Medicines Agency has approved its use when capecitabine or 5-FU is discontinued due to HFS or CVT. However, in the adjuvant setting, data on its safety profile are scarce. We assessed the feasibility of S-1 in patients who discontinued capecitabine due to HFS or CVT. METHODS: We included all patients with colon cancer included in the Prospective Dutch Colorectal Cancer Cohort (PLCRC), who switched from capecitabine to S-1 due to HFS or CVT, in the adjuvant treatment setting between March 2018 and May 2025. We assessed the completion rate of adjuvant treatment as well as toxicity following switch to S-1. RESULTS: A total of 55 patients with colon cancer were analyzed. Reason to switch from capecitabine to S-1 was HFS in 42 % (n = 23) and CVT in 53 % (n = 29) of patients. 91 % (n = 21) of patients who switched to S-1 for HFS and 97 % (n = 28) for CVT experienced a lower grade or complete resolution of symptoms. 80 % (n = 44) of patients were able to complete adjuvant treatment after the switch. Persistent HFS led to early discontinuation in 9 % (2/23), with no discontinuation due to CVT recurrence. CONCLUSION: S-1 is a feasible and useful alternative for patients with colon cancer experiencing capecitabine-induced HFS or CVT in the adjuvant setting and allows the continuation of potentially curative fluoropyrimidine-based treatment.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Ghedri A, van der Baan FH, Otten JMMB, et al. Safety and feasibility of S-1 after capecitabine-induced toxicity in the adjuvant treatment of colon cancer patients: A population-based real-world study. Eur J Cancer. 2026. PMID: 41724114. doi:10.1016/j.ejca.2026.116588

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。